Article Versions Notes

Albanese M, Marrone G, Paolino A, Di Lauro M, Di Daniele F, Chiaramonte C, D’Agostini C, Romani A, Cavaliere A, Guerriero C, et al. Effects of Ultramicronized Palmitoylethanolamide (um-PEA) in COVID-19 Early Stages: A Case–Control Study. Pharmaceuticals. 2022; 15(2):253. https://doi.org/10.3390/ph15020253

Albanese, Maria, Giulia Marrone, Agostino Paolino, Manuela Di Lauro, Francesca Di Daniele, Carlo Chiaramonte, Cartesio D’Agostini, Annalisa Romani, Alessandro Cavaliere, Cristina Guerriero, and et al. 2022. "Effects of Ultramicronized Palmitoylethanolamide (um-PEA) in COVID-19 Early Stages: A Case–Control Study" Pharmaceuticals 15, no. 2: 253. https://doi.org/10.3390/ph15020253

Albanese, M., Marrone, G., Paolino, A., Di Lauro, M., Di Daniele, F., Chiaramonte, C., D’Agostini, C., Romani, A., Cavaliere, A., Guerriero, C., Magrini, A., Mercuri, N. B., Di Daniele, N., & Noce, A. (2022). Effects of Ultramicronized Palmitoylethanolamide (um-PEA) in COVID-19 Early Stages: A Case–Control Study. Pharmaceuticals, 15(2), 253. https://doi.org/10.3390/ph15020253